Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Prepaid Assets: 2022-2025

Historic Prepaid Assets for Axsome Therapeutics (AXSM) over the last 4 years, with Sep 2025 value amounting to $19.8 million.

  • Axsome Therapeutics' Prepaid Assets rose 47.56% to $19.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.8 million, marking a year-over-year increase of 47.56%. This contributed to the annual value of $12.0 million for FY2024, which is 47.60% up from last year.
  • Axsome Therapeutics' Prepaid Assets amounted to $19.8 million in Q3 2025, which was up 21.12% from $16.3 million recorded in Q2 2025.
  • Axsome Therapeutics' Prepaid Assets' 5-year high stood at $19.8 million during Q3 2025, with a 5-year trough of $2.1 million in Q1 2022.
  • Over the past 3 years, Axsome Therapeutics' median Prepaid Assets value was $12.0 million (recorded in 2024), while the average stood at $11.6 million.
  • Data for Axsome Therapeutics' Prepaid Assets shows a peak YoY skyrocketed of 191.80% (in 2023) over the last 5 years.
  • Over the past 4 years, Axsome Therapeutics' Prepaid Assets (Quarterly) stood at $2.8 million in 2022, then spiked by 191.80% to $8.1 million in 2023, then surged by 47.60% to $12.0 million in 2024, then surged by 47.56% to $19.8 million in 2025.
  • Its Prepaid Assets was $19.8 million in Q3 2025, compared to $16.3 million in Q2 2025 and $16.0 million in Q1 2025.